BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidance

What This Product Solves

BFH772 is a potent and selective VEGFR2 inhibitor, specifically engineered for research applications centering on VEGFR2-mediated angiogenesis. Given its high affinity (IC₅₀ = 3 nM) and over 500-fold selectivity for VEGFR2 versus related kinases, BFH772 enables precise modulation of the VEGFR2 signaling pathway without significant off-target effects. This makes it an actionable tool for studies investigating the molecular mechanisms of angiogenesis, tumor growth, and selective anti-angiogenic agent responses in preclinical models. Its selectivity profile is particularly advantageous in workflows that require minimal cross-reactivity with other receptor tyrosine kinases or unrelated kinases such as B-RAF, RET, or TIE-2. For researchers seeking to dissect VEGFR2-driven processes or evaluate anti-angiogenic strategies, BFH772 fills a critical niche where broad-spectrum kinase inhibitors would confound data interpretation.

Protocol Parameters

• Assay: VEGFR2 kinase inhibition
  Value: IC₅₀ = 3 nM
  Applicability: Use in cell-based or biochemical assays targeting VEGFR2-driven pathways.
  Rationale: High potency enables precise titration and minimal compound wastage.
  Source type: product information
• Assay: Compound dissolution
  Value: ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol; insoluble in water
  Applicability: Prepare stock solutions in DMSO or ethanol for in vitro and in vivo studies.
  Rationale: Ensures compound stability and accurate dosing; water-based systems are incompatible.
  Source type: product information
• Assay: Storage conditions
  Value: -20℃ (dry, desiccated, protected from light); avoid long-term storage of solutions
  Applicability: Solid material can be stored for extended periods; freshly prepare solutions for each experiment.
  Rationale: Prevents compound degradation and maintains reproducible activity.
  Source type: product information
• Assay: Selectivity profile
  Value: >500-fold lower potency for FLK-1, FLT-1, FLT-4; ~40-fold for B-RAF, RET, TIE-2
  Applicability: Use when off-target kinase inhibition must be minimized.
  Rationale: Ensures biological effects are attributed to VEGFR2 inhibition.
  Source type: product information

Workflow Setup and QC Checklist

To ensure data quality and experimental reproducibility with BFH772, adhere to the following setup and quality control steps:

• Stock Solution Preparation: Dissolve BFH772 in DMSO or ethanol to the desired stock concentration (e.g., 10-50 mM), ensuring complete dissolution by vortexing and brief sonication if necessary. Water should not be used due to insolubility.
• Aliquoting: Prepare small aliquots to minimize repeated freeze-thaw cycles. Discard any unused aliquots after a single thaw to prevent degradation.
• Storage: Store solid compound at -20°C in a desiccator, protected from light. For working solutions, prepare freshly before use and avoid storage beyond several hours, even at low temperature.
• Purity Verification: Confirm that the batch purity is above 96% by reviewing the provided certificate of analysis.
• QC Documentation: Retain batch-specific certificates and safety data sheets for compliance and troubleshooting.
• Compatibility Check: Ensure that assay buffers and cell culture conditions are compatible with residual DMSO or ethanol (typically ≤0.1% v/v in final assay wells).

For additional procedural detail, see related guidance in BFH772 (VEGFR2 inhibitor): Technical Workflow and QC Guidance, which elaborates on solubility and selectivity considerations, and BFH772 (VEGFR2 inhibitor): Practical Use in Angiogenesis Research for context-specific workflow integrations.

Common Failure Modes and Fixes

• Poor Compound Solubilization: If undissolved material is visible after dissolution, increase vortexing duration, apply mild sonication, or warm slightly (<37°C); always filter solutions before use if particulates persist.
• Loss of Activity: Activity loss may result from long-term storage of dissolved BFH772; always prepare fresh solutions and avoid storing dissolved compound for over 24 hours, even at -20°C.
• Unexpected Cytotoxicity: High DMSO or ethanol concentrations can cause cytotoxicity; ensure solvent levels in assays do not exceed tolerated limits for your cell system.
• Confounding Off-Target Effects: Although selectivity is high, always include appropriate controls to distinguish VEGFR2-specific effects, especially in complex biological systems.
• Batch Variability: Use only batches with verified purity and cross-check batch numbers with associated quality documentation.

Scope and Limitations

• Water Solubility: Due to insolubility in water, BFH772 is incompatible with protocols that do not tolerate organic solvents.
• Selective Application: Not appropriate for studies requiring broad kinase inhibition or targeting non-VEGFR2 signaling pathways.
• In Vivo Use: Oral administration has been validated in animal tumor models as per product dossier, but always verify formulation compatibility and dosing regimens for your specific model.
• Reproducibility: Strict adherence to solubility and storage guidelines is necessary; deviations can lead to loss of activity or inconsistent results.

Conclusion

BFH772 offers researchers a highly selective and potent tool for investigating VEGFR2-driven angiogenesis, particularly within tumor models. Its solubility and selectivity profiles demand careful protocol design, with a focus on solvent compatibility and rigorous quality control. For workflows requiring precise VEGFR2 pathway inhibition with minimal confounding off-target effects, BFH772 (VEGFR2 inhibitor) provides a robust solution. For further context on protocol design and technical considerations, refer to existing internal articles as cited above. As always, consult the product's certificate of analysis and safety data for batch-specific guidance and compliance.